This combination tablet contains Dapagliflozin 10mg, Sitagliptin 100mg, and Metformin (Extended Release) 500mg, designed for the management of type 2 diabetes mellitus. Dapagliflozin is a SGLT2 inhibitor that helps lower blood glucose by increasing urinary glucose excretion. Sitagliptin is a DPP-4 inhibitor that enhances the body’s incretin system, improving insulin release and reducing glucagon levels. Metformin (ER) is a biguanide that decreases hepatic glucose production and improves insulin sensitivity, maintaining stable blood glucose levels throughout the day. This combination is especially useful for patients who require multiple mechanisms to control hyperglycemia effectively. It supports glycemic control while minimizing the risk of hypoglycemia when used as prescribed.
